Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) As a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy Against Canine Soft Tissue Sarcomas

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2020 Jul 16

PMID 32664672

Citations 4

Authors

Ivan Petrov

Ivaylo Gentschev

Anna Vyalkova

Mohamed I Elashry

Michele C Klymiuk

Stefan Arnhold

Aladar A Szalay

Affiliations

Soon will be listed here.

Abstract

Several oncolytic viruses (OVs) including various human and canine adenoviruses, canine distemper virus, herpes-simplex virus, reovirus, and members of the poxvirus family, such as vaccinia virus and myxoma virus, have been successfully tested for canine cancer therapy in preclinical and clinical settings. The success of the cancer virotherapy is dependent on the ability of oncolytic viruses to overcome the attacks of the host immune system, to preferentially infect and lyse cancer cells, and to initiate tumor-specific immunity. To date, several different strategies have been developed to overcome the antiviral host defense barriers. In our study, we used canine adipose-derived mesenchymal stem cells (cAdMSCs) as a "Trojan horse" for the delivery of oncolytic vaccinia virus Copenhagen strain to achieve maximum oncolysis against canine soft tissue sarcoma (CSTS) tumors. A single systemic administration of vaccinia virus-loaded cAdMSCs was found to be safe and led to the significant reduction and substantial inhibition of tumor growth in a CSTS xenograft mouse model. This is the first example that vaccinia virus-loaded cAdMSCs could serve as a therapeutic agent against CSTS tumors.

Citing Articles

Characterisation and Sensitivity of a Canine Mast Cell Tumour Line to Oncolytic Viruses.

Mehrani Y, Kakish J, Napoleoni C, Thompson J, Knapp J, Minott J Vet Comp Oncol. 2024; 23(1):42-51.

PMID: 39526468 PMC: 11830461. DOI: 10.1111/vco.13024.

Bioengineered Mesenchymal Stem/Stromal Cells in Anti-Cancer Therapy: Current Trends and Future Prospects.

Gil-Chinchilla J, Zapata A, Moraleda J, Garcia-Bernal D Biomolecules. 2024; 14(7).

PMID: 39062449 PMC: 11275142. DOI: 10.3390/biom14070734.

Effect of storage conditions on the quality of equine and canine mesenchymal stem cell derived nanoparticles including extracellular vesicles for research and therapy.

Klymiuk M, Balz N, Elashry M, Wenisch S, Arnhold S Discov Nano. 2024; 19(1):80.

PMID: 38700790 PMC: 11068712. DOI: 10.1186/s11671-024-04026-4.

Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients.

Martin-Carrasco C, Delgado-Bonet P, Tomeo-Martin B, Pastor J, de la Riva C, Palau-Concejo P Vet Sci. 2022; 9(7).

PMID: 35878344 PMC: 9316846. DOI: 10.3390/vetsci9070327.

Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality.

Nava D, Selvi K, Alonso M Front Immunol. 2022; 13:866892.

PMID: 35493490 PMC: 9043602. DOI: 10.3389/fimmu.2022.866892.

References

Ikeda K, Ichikawa T, Wakimoto H, Silver J, Deisboeck T, Finkelstein D . Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999; 5(8):881-7. DOI: 10.1038/11320. View

Greish K, Frandsen J, Scharff S, Gustafson J, Cappello J, Li D . Silk-elastinlike protein polymers improve the efficacy of adenovirus thymidine kinase enzyme prodrug therapy of head and neck tumors. J Gene Med. 2010; 12(7):572-9. PMC: 2906606. DOI: 10.1002/jgm.1469. View

Reich C, Raabe O, Wenisch S, Bridger P, Kramer M, Arnhold S . Isolation, culture and chondrogenic differentiation of canine adipose tissue- and bone marrow-derived mesenchymal stem cells--a comparative study. Vet Res Commun. 2012; 36(2):139-48. DOI: 10.1007/s11259-012-9523-0. View

Cejalvo T, Perise-Barrios A, Del Portillo I, Laborda E, Rodriguez-Milla M, Cubillo I . Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy. Cancer Res. 2018; 78(17):4891-4901. DOI: 10.1158/0008-5472.CAN-17-3754. View

Scioli M, Storti G, DAmico F, Gentile P, Kim B, Cervelli V . Adipose-Derived Stem Cells in Cancer Progression: New Perspectives and Opportunities. Int J Mol Sci. 2019; 20(13). PMC: 6651808. DOI: 10.3390/ijms20133296. View

Fisher K, Seymour L . HPMA copolymers for masking and retargeting of therapeutic viruses. Adv Drug Deliv Rev. 2009; 62(2):240-5. DOI: 10.1016/j.addr.2009.12.003. View

Gentschev I, Patil S, Adelfinger M, Weibel S, Geissinger U, Frentzen A . Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered. 2012; 4(2):84-9. PMC: 3609626. DOI: 10.4161/bioe.22462. View

Fork M, Murua Escobar H, Soller J, Sterenczak K, Willenbrock S, Winkler S . Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258. BMC Cancer. 2008; 8:240. PMC: 2527616. DOI: 10.1186/1471-2407-8-240. View

Schrepfer S, Deuse T, Reichenspurner H, Fischbein M, Robbins R, Pelletier M . Stem cell transplantation: the lung barrier. Transplant Proc. 2007; 39(2):573-6. DOI: 10.1016/j.transproceed.2006.12.019. View

10.

Russell K, Chow N, Dukoff D, Gibson T, LaMarre J, Betts D . Characterization and Immunomodulatory Effects of Canine Adipose Tissue- and Bone Marrow-Derived Mesenchymal Stromal Cells. PLoS One. 2016; 11(12):e0167442. PMC: 5131977. DOI: 10.1371/journal.pone.0167442. View

11.

Ong H, Hasegawa K, Dietz A, Russell S, Peng K . Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 2006; 14(4):324-33. DOI: 10.1038/sj.gt.3302880. View

12.

Fujiwara S, Nawa A, Luo C, Kamakura M, Goshima F, Kondo C . Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther. 2010; 18(2):77-86. PMC: 3025316. DOI: 10.1038/cgt.2010.53. View

13.

Muller M, Raabe O, Addicks K, Wenisch S, Arnhold S . Effects of non-steroidal anti-inflammatory drugs on proliferation, differentiation and migration in equine mesenchymal stem cells. Cell Biol Int. 2010; 35(3):235-48. DOI: 10.1042/CBI20090211. View

14.

Fritz V, Jorgensen C . Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr Stem Cell Res Ther. 2008; 3(1):32-42. DOI: 10.2174/157488808783489462. View

15.

Gentschev I, Patil S, Petrov I, Cappello J, Adelfinger M, Szalay A . Oncolytic virotherapy of canine and feline cancer. Viruses. 2014; 6(5):2122-37. PMC: 4036544. DOI: 10.3390/v6052122. View

16.

Donat U, Weibel S, Hess M, Stritzker J, Hartl B, Sturm J . Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice. PLoS One. 2012; 7(9):e45942. PMC: 3457966. DOI: 10.1371/journal.pone.0045942. View

17.

MacNeill A . On the potential of oncolytic virotherapy for the treatment of canine cancers. Oncolytic Virother. 2016; 4:95-107. PMC: 4918385. DOI: 10.2147/OV.S66358. View

18.

Draganov D, Santidrian A, Minev I, Nguyen D, Kilinc M, Petrov I . Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers. J Transl Med. 2019; 17(1):100. PMC: 6437877. DOI: 10.1186/s12967-019-1829-z. View

19.

Sanchez D, Cesarman-Maus G, Amador-Molina A, Lizano M . Oncolytic Viruses for Canine Cancer Treatment. Cancers (Basel). 2018; 10(11). PMC: 6266482. DOI: 10.3390/cancers10110404. View

20.

Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U . Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One. 2012; 7(5):e37239. PMC: 3352892. DOI: 10.1371/journal.pone.0037239. View